ArticleDermatology practical & conceptual2025
Differential Expression of Claudin-3 and Claudin-1 in Mycosis Fungoides: Implications for Disease Monitoring.
Article in Dermatology practical & conceptual, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionClaudins are integral transmembrane proteins that play a pivotal role in regulating tight junctions within epithelial and endothelial cells. In addition to their fundamental function in preserving cell-cell adhesion and barrier integrity, claudins are implicated in various biological processes, including those critical to cancer development and dermatological disorders. However, the role of claudin-1 and claudin-3 in mycosis fungoides (MF) pathogenesis remains unexplored and has yet to be comprehensively studied.
objectivesThis study aimed to investigate the serum levels of claudin-1 and claudin-3 in MF patients and assess their potential clinical significance as biomarkers for disease progression.
methodsA total of 88 MF patients and 88 healthy controls were included in this case-control study. Serum claudin-1 and claudin-3 levels were measured using enzyme-linked immunosorbent assay (ELISA). Statistical analyses were performed to compare claudin levels between groups and examine correlations with disease stage and duration.
resultsSerum claudin-3 levels were significantly higher in MF patients compared to controls (P<0.001), while no significant difference was observed in claudin-1 levels (P=0.448). Additionally, a weak but statistically significant positive correlation was found between claudin-3 levels and MF stage (r=0.219, P=0.041), suggesting its potential role in disease progression. No significant correlation was observed between claudin-1 levels and MF stage.
conclusionOur findings indicate that elevated serum claudin-3 levels are associated with MF and correlate with disease severity, suggesting that claudin-3 may serve as a valuable biomarker for monitoring disease progression. Further research is required to elucidate its underlying mechanisms and assess its potential as a therapeutic target in MF.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.